A Phase 2 interventional study of Tislelizumab and Paclitaxel in Resectable Esophageal Squamous Cell Carcinoma, sponsored by BeiGene. Completed at 8 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-12-01.
Sponsored by BeiGene · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 23 studies testing tislelizumab in Esophageal Squamous Cell Carcinoma — 13 open to participants now, 15 under way, 1 of them phase 3. tislelizumab · Esophageal Squamous Cell Carcinoma.
Among the 23 studies testing tislelizumab in Esophageal Squamous Cell Carcinoma, this one is the 10th largest by enrollment, is one of 2 that started in 2021, is one of 14 in phase 2, and was the 5th registered.
678 studies on the registry are indexed under Esophageal Squamous Cell Carcinoma; 269 are open to participants now.
Browse Esophageal Squamous Cell Carcinoma studies →13 of the 23 studies testing tislelizumab in Esophageal Squamous Cell Carcinoma are open now, in 4 countries. Recruiting first, the newest first:
BeOne Medicines · Sites in Japan
Ages 18+
BeOne Medicines · Sites in United States
Ages 18+
Ming-Yu Lien · Sites in Taiwan
Ages 20+
Shanghai Zhongshan Hospital · Sites in China
Ages 18+
Sichuan University · Sites in China
Ages 18–75
By country, each count listing its studies:
tislelizumab: first FDA approval 2024 (TEVIMBRA), first EMA approval 2023. What it is approved for, and how studies give it, is on its page →
Of the 180 Esophageal Squamous Cell Carcinoma studies recruiting now, 83 (46%) set no upper age limit and 76 (42%) stop at 75 or younger; 3 take children under 18; 8 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
23 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 17 · Phase 3 4 · Phase 4 1
First in 2018; this study’s year is marked. 2 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 70 is close to the median of 64 across 564 interventional studies indexed under Esophageal Squamous Cell Carcinoma.
Median enrollment 50 across the 23 interventional studies. Of the 6 that completed or were terminated, 5 (83%) have results posted.
This tab as a report to print or save as PDF → With an account.
7 of 23 have an industry lead sponsor. The 10 most frequent:
This study is registered under BeiGene, one of the names counted as BeOne Medicines. Under that name alone:
BeiGene is the lead sponsor of 125 studies on the registry; 2 are open to participants now.
Of its 55 completed or terminated interventional studies of FDA-regulated products, 32 (58%) have results posted.
10 studies in Esophageal Squamous Cell Carcinoma by BeOne Medicines: 2 open now, 2 under way, none of them phase 3. Of 8 finished, 6 (75%) have results posted.
Among the 10 studies in Esophageal Squamous Cell Carcinoma by BeOne Medicines, this one is the 7th largest by enrollment, is one of 2 that started in 2021, is one of 7 in phase 2, and was the 6th registered.
BeOne Medicines’s Esophageal Squamous Cell Carcinoma studies by the year they started, since 2017.
1 of the studies testing tislelizumab in Esophageal Squamous Cell Carcinoma that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07317609Shanghai Zhongshan HospitalNeoadjuvant Immunotherapy Combined With Chemotherapy Sequenced With Endoscopic Resection for Esophageal Cancer (Endosurgery-02) | 2027-09-30 |
Add it to your calendar (.ics) → With an account.
Among the 23 studies testing tislelizumab in Esophageal Squamous Cell Carcinoma, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among BeOne Medicines’s 10 in Esophageal Squamous Cell Carcinoma:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the pathological complete response (pCR) in participants receiving tislelizumab plus chemotherapy/chemoradiotherapy as neoadjuvant treatment.
This study enrolled participants with esophageal squamous cell carcinoma who were eligible to have their tumor removed by surgery (also called surgical resection). The treatment phase of the study included the following:
Neoadjuvant therapy (neoadjuvant refers to treatment that occurs before surgery, which can make the tumor easier to remove). In this study participants received neoadjuvant therapy based on their response to induction therapy. Response to induction therapy was assessed using the maximum standardized uptake value (SUVmax) measured using a Positron Emission Tomography (PET) scan. The SUV number refers to the level of brightness on the PET scan which reflects metabolic activity; increased metabolic activity can indicate cancerous growth.
After surgery participants were followed until death, lost to follow-up, withdrawal of consent, or until the study was completed
Key Inclusion Criteria:
Key Exclusion Criteria:
Any condition requiring systemic treatment with either (> 10 mg daily prednisone or equivalent) or other medications within 14 days before first dose.
* Adrenal replacement steroid (dose ≤ 10 mg daily of prednisone or equivalent) and topical, ocular, intra-articular, intranasal, or inhaled corticosteroid with minimal systemic absorption, and short course (≤ 7 days) of corticosteroid prescribed prophylactically or for the treatment of a non- condition are permitted.
Active autoimmune diseases or history of autoimmune diseases that may relapse.
* Controlled Type I diabetes, hypothyroidism only requiring hormone replacement, controlled celiac disease, skin diseases (such as vitiligo, psoriasis, or alopecia) not requiring systemic treatment, or conditions not expected to recur in the absence of an external trigger are permitted to enroll.
With infections requiring systemic antibacterial, antifungal, or antiviral therapy, including tuberculosis infection.
Note: Other protocol defined Inclusion/Exclusion criteria may apply.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received induction therapy of one 21-day cycle with cisplatin and paclitaxel administered on Day 1. Following the induction phase, participants with a decrease in positron emission tomography (PET) Standardized Uptake Value (SUV)max ≥ 35% then received neoadjuvant therapy consisting of 200 mg tislelizumab on Day 1 of each 21-day cycle for 3 cycles and chemotherapy doublet (cisplatin + paclitaxel) for 2 cycles. After neoadjuvant treatment, participants were assessed for disease resectability and underwent surgical resection of the tumor approximately 4 to 6 weeks later.
Drug: Tislelizumab · Drug: Paclitaxel · Drug: Cisplatin · Procedure: Surgical resection
Participants received induction therapy of one 21-day cycle with cisplatin and paclitaxel administered on Day 1. Following the induction phase, participants with a decrease in PET SUVmax \< 35% then received neoadjuvant therapy consisting of 200 mg tislelizumab on Day 1 of each 21-day cycle for 3 cycles and investigator-chosen chemotherapy doublet (paclitaxel + cisplatin or 5-fluorouracil + cisplatin) for 2 cycles plus concurrent radiotherapy. After neoadjuvant treatment, participants were assessed for disease resectability and underwent surgical resection of the tumor approximately 4 to 6 weeks later.
Drug: Tislelizumab · Drug: Paclitaxel · Drug: Cisplatin · Drug: 5-fluorouracil · Radiation: Radiotherapy · Procedure: Surgical resection
Administered intravenously on Day 1 of each 21-Day Cycle.
Also known as: BGB-A317
135 mg/m\^2 administered intravenously on Day 1 of each 21-Day Cycle.
80 mg/m\^2 administered intravenously on Day 1 of each 21-Day Cycle.
1000 mg/m\^2 administered intravenously over Day 1 through 4 of each 21-Day Cycle.
40 grays/20 fractions
Performed as indicated in the treatment arm.
Pathological Complete Response (pCR) Rate
The pCR rate was defined as the percentage of participants with absence of residual tumor in the resected primary tumor and all resected lymph nodes after completion of neoadjuvant treatment. pCR rates were assessed by a pathologist at each site.
Time frame: pCR was determined from samples taken during surgery; surgery occurred 4-6 weeks after the last dose of chemotherapy, approximately Day 71-86
R0 Resection Rate
Defined as the percentage of participants with R0 resection. R0 resection refers to a surgical procedure where the entire tumor is completely removed with no evidence of residual cancer tissue at the surgical margins.
Time frame: Resection was planned to occur 4-6 weeks after the last dose of chemotherapy, approximately Day 71-86
1-year/3-year Disease-free Survival (DFS) Rate
The DFS rate is defined as the percentage of participants free from disease events at 1 year and 3 years after the first date of no disease (R0 resection as surgery outcome). Disease events include local or distant recurrence or death due to any cause. The DFS rate was analyzed only for participants who underwent R0 resection. Disease-free rates were estimated using the Kaplan-Meier method with 95% confidence intervals estimated using the Greenwood formula.
Time frame: 1 year and 3 years after surgery
1-year/3-year Event-free Survival (EFS) Rate
The EFS rate is defined as the percentage of participants free from EFS events at 1 year and 3 years after the first dose. The EFS events include progression of disease that precludes definitive surgery, local or distant recurrence, or death due to any cause. Event-free rates were estimated using the Kaplan-Meier method with 95% confidence intervals estimated using the Greenwood formula.
Time frame: 1 year and 3 years after first dose date
Objective Response Rate (ORR)
The ORR is defined as the percentage of participants who have a complete response or partial response before surgery as assessed by the investigator per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1) in all participants with measurable disease at baseline. Tumor response was assessed by computed tomography (CT) or magnetic resonance imaging (MRI) of the neck, chest, and abdomen. Complete Response (CR): Disappearance of all target lesions. Any pathological lymph nodes (whether target or nontarget) must have reduction in short axis to \< 10 mm. Partial Response (PR): At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.
Time frame: ORR was assessed prior to surgery, Day 71 to 86
Number Of Participants Experiencing Treatment-Emergent Adverse Events
Immune-mediated AEs were reported until 90 days after the last dose of tislelizumab
Time frame: From the first dose of study drug up to 30 days after last dose of any component of treatment or surgery or the initiation of subsequent anticancer therapy, whichever occurred first. Up to approximately 9 months.
This study was conducted at 8 study centers in China.
| Milestone | Cohort A (Responder) | Cohort B (Non-responder) |
|---|---|---|
| Started | 30 | 40 |
| Surgical resection performed | 21 | 33 |
| Completed | 0 | 0 |
| Not completed | 30 | 40 |
| Withdrew: Sponsor ended study | 20 | 22 |
| Withdrew: Death | 8 | 17 |
| Withdrew: Lost to follow-up | 2 | 0 |
| Withdrew: Withdrawal by subject | 0 | 1 |
The pCR rate was defined as the percentage of participants with absence of residual tumor in the resected primary tumor and all resected lymph nodes after completion of neoadjuvant treatment. pCR rates were assessed by a pathologist at each site.
| percentage of participants | Cohort A (Responder) | Cohort B (Non-responder) |
|---|---|---|
| Pathological Complete Response (pCR) Rate | 30.0 (11.9 to 54.3) | 34.4 (18.6 to 53.2) |
Defined as the percentage of participants with R0 resection. R0 resection refers to a surgical procedure where the entire tumor is completely removed with no evidence of residual cancer tissue at the surgical margins.
| percentage of participants | Cohort A (Responder) | Cohort B (Non-responder) |
|---|---|---|
| R0 Resection Rate | 95.0 | 90.6 |
The DFS rate is defined as the percentage of participants free from disease events at 1 year and 3 years after the first date of no disease (R0 resection as surgery outcome). Disease events include local or distant recurrence or death due to any cause. The DFS rate was analyzed only for participants who underwent R0 resection. Disease-free rates were estimated using the Kaplan-Meier method with 95% confidence intervals estimated using the Greenwood formula.
| percentage of participants | Cohort A (Responder) | Cohort B (Non-responder) |
|---|---|---|
| 1 Year | 79.0 (47.9 to 92.7) | 74.2 (53.3 to 86.8) |
The EFS rate is defined as the percentage of participants free from EFS events at 1 year and 3 years after the first dose. The EFS events include progression of disease that precludes definitive surgery, local or distant recurrence, or death due to any cause. Event-free rates were estimated using the Kaplan-Meier method with 95% confidence intervals estimated using the Greenwood formula.
| percentage of participants | Cohort A (Responder) | Cohort B (Non-responder) |
|---|---|---|
| 1 Year | 87.1 (64.3 to 95.8) | 67.8 (48.3 to 81.2) |
| 3 Years | 75.5 (49.8 to 89.3) | 59.9 (40.0 to 75.1) |
The ORR is defined as the percentage of participants who have a complete response or partial response before surgery as assessed by the investigator per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1) in all participants with measurable disease at baseline. Tumor response was assessed by computed tomography (CT) or magnetic resonance imaging (MRI) of the neck, chest, and abdomen. Complete Response (CR): Disappearance of all target lesions. Any pathological lymph nodes (whether target or nontarget) must have reduction in short axis to \< 10 mm. Partial Response (PR): At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.
| percentage of participants | Cohort A (Responder) | Cohort B (Non-responder) |
|---|---|---|
| Objective Response Rate (ORR) | 71.4 (47.8 to 88.7) | 42.4 (25.5 to 60.8) |
Immune-mediated AEs were reported until 90 days after the last dose of tislelizumab
| Participants | Cohort A (Responder) | Cohort B (Non-responder) |
|---|---|---|
| Number Of Participants Experiencing Treatment-Emergent Adverse Events | 30 | 39 |
Collected over All-cause-mortality: From first dose until the end of study; maximum time on study follow-up was 37.3 months. AEs: From the first dose of study drug up to 30 days after the last treatment (any component of combination treatment or surgery, whichever is last) or the initiation of subsequent anticancer therapy, whichever occurred first. Immune-mediated AEs were reported until 90 days after the last dose of tislelizumab, up to approximately 9 months.. Non-serious events are listed at a 3% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Cohort A (Responder) | 8/30 (26.7%) | 8/30 (26.7%) | 30/30 (100%) |
| Cohort B (Non-responder) | 17/40 (42.5%) | 12/40 (30%) | 39/40 (97.5%) |
| Event | Cohort A (Responder) | Cohort B (Non-responder) |
|---|---|---|
| PneumoniaInfections and infestations | 0/30 | 2/40 |
| Neutrophil count decreasedInvestigations | 1/30 | 2/40 |
| Acute coronary syndromeCardiac disorders | 1/30 | 0/40 |
| Immune-mediated myocarditisCardiac disorders | 1/30 | 0/40 |
| Abdominal painGastrointestinal disorders | 1/30 | 0/40 |
| DysphagiaGastrointestinal disorders | 1/30 | 1/40 |
| Upper gastrointestinal haemorrhageGastrointestinal disorders | 1/30 | 0/40 |
| FatigueGeneral disorders | 1/30 | 0/40 |
| Gastrointestinal anastomotic leakInjury, poisoning and procedural complications | 1/30 | 0/40 |
| White blood cell count decreasedInvestigations | 1/30 | 1/40 |
| Event | Cohort A (Responder) | Cohort B (Non-responder) |
|---|---|---|
| White blood cell count decreasedInvestigations | 19/30 | 35/40 |
| Neutrophil count decreasedInvestigations | 19/30 | 34/40 |
| AnaemiaBlood and lymphatic system disorders | 21/30 | 32/40 |
| VomitingGastrointestinal disorders | 10/30 | 16/40 |
| HypoalbuminaemiaMetabolism and nutrition disorders | 4/30 | 16/40 |
| NauseaGastrointestinal disorders | 11/30 | 14/40 |
| Platelet count decreasedInvestigations | 7/30 | 12/40 |
| HypokalaemiaMetabolism and nutrition disorders | 6/30 | 11/40 |
| Weight decreasedInvestigations | 3/30 | 10/40 |
| HyperglycaemiaMetabolism and nutrition disorders | 3/30 | 10/40 |
| Age, Continuous(years) | Cohort A (Responder) | Cohort B (Non-responder) | Total |
|---|---|---|---|
| Mean | 64.6 ± 8.16 | 63.1 ± 7.06 | 63.7 ± 7.53 |
| Sex: Female, Male(Participants) | Cohort A (Responder) | Cohort B (Non-responder) | Total |
|---|---|---|---|
| Female | 6 | 2 | 8 |
| Male | 24 | 38 | 62 |
| Ethnicity (NIH/OMB)(Participants) | Cohort A (Responder) | Cohort B (Non-responder) | Total |
|---|---|---|---|
| Hispanic or Latino | 0 | 0 | 0 |
| Not Hispanic or Latino | 30 | 40 | 70 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Cohort A (Responder) | Cohort B (Non-responder) | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 30 | 40 | 70 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 |
| White | 0 | 0 | 0 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Region of Enrollment(participants) | Cohort A (Responder) | Cohort B (Non-responder) | Total |
|---|---|---|---|
| China | 30 | 40 | 70 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — BeiGene shares data on completed studies responsibly and provides qualified scientific and medical researchers access to data and supporting documentation for clinical trials in dossiers for medicines and indications after submission and approval in the United States, China, and Europe. Clinical trials supporting subsequent local approvals, new indications, or combination products are eligible for sharing once corresponding regulatory approvals are achieved. BeiGene shares data only when permitted by applicable data privacy and security laws and regulations, when it is feasible to do so without compromising the privacy of study participants, and other considerations. Qualified researchers with appropriate competencies who are engaged in novel scientific research may submit a request for participant-level data with a research proposal for BeiGene review. Research teams must include a biostatistician and sign a Data Sharing Agreement prior to receiving access to clinical trial data.
Supporting information: Study protocol, Statistical analysis plan, Clinical study report
Time frame: See plan description
Access criteria: See plan description
Data sharing details ↗ · beigene.com
Ran from Aug 2021 to primary completion in Apr 2023, 20 months.
Results were first posted in Dec 2025, 2 years 7 months after primary completion.
Of 173 phase 2 interventional studies under Esophageal Squamous Cell Carcinoma, half reached primary completion within 40 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 52. This study's 20 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Tislelizumab
Esophageal Squamous Cell Carcinoma →